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Abstract
Background: Independent luciferase reporter assays and fluorescent translocation assays have
been successfully used in drug discovery for several molecular targets. We developed U2transLUC,
an assay system in which luciferase and fluorescent read-outs can be multiplexed to provide a
powerful cell-based high content screening method.
Results: The U2transLUC system is based on a stable cell line expressing a GFP-tagged FOXO
transcription factor and a luciferase reporter gene under the control of human FOXO-responsive
enhancers. The U2transLUC assay measures nuclear-cytoplasmic FOXO shuttling and FOXO-
driven transcription, providing a means to analyze these two key features of FOXO regulation in
the same experiment. We challenged the U2transLUC system with chemical probes with known
biological activities and we were able to identify compounds with translocation and/or
transactivation capacity.
Conclusion: Combining different biological read-outs in a single cell line offers significant
advantages over conventional cell-based assays. The U2transLUC assay facilitates the maintenance
and monitoring of homogeneous FOXO transcription factor expression and allows the reporter
gene activity measured to be normalized with respect to cell viability. U2transLUC is suitable for
high throughput screening and can identify small molecules that interfere with FOXO signaling at
different levels.
Background
Forkhead box O (FOXO) proteins are emerging as tran-
scriptional integrators of pathways that regulate a variety
of cellular processes, including differentiation, metabo-
lism, stress response, cell cycle and apoptosis [1-3]. FOXO
transcription factors have been proposed to act as bona fide
tumor suppressors due to their inhibitory effects on cell
cycle and survival [4], properties mediated by their bind-
ing as monomers to consensus DNA binding sites. Their
transcriptional activity is governed by a network of signal-
ing events, the best recognized of which is the phosphor-
ylation of FOXO proteins at three highly conserved serine
and threonine residues by Akt that provokes its associa-
tion with 14-3-3 protein and in turn, the nuclear exclu-
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FOXO from the nucleus to the cytoplasm alone cannot
account for the inhibitory effect of PI3K/Akt signaling on
FOXO activity since a nuclear form of FOXO1 in which
the nuclear export sequence is disrupted is still inhibited
by the PI3K/Akt pathway [5]. Indeed, the introduction of
a negative charge in the positively charged DNA binding
domain by means of FOXO phosphorylation at the sec-
ond of the three Akt consensus sites inhibits DNA binding
of FOXO [6,7]. The FOXO DNA interaction is also regu-
lated by the transfer of acetyl groups to lysine residues in
FOXO proteins by the histone acetyltransferases (HATs)
CBP and p300 [2], which alters the DNA binding capacity
of FOXO1 and FOXO3a [8]. Conversely, Sirt1 deacety-
lases deacetylate FOXO factors and regulate their DNA
binding at specific target genes. Taken together, these
observations suggest that translocation and transactiva-
tion are different and separate means to regulate FOXO.
However, large scale tools are not available to assess the
different levels of FOXO regulation. Therefore systematic
chemical genetic or loss of function studies to investigate
the complex regulation of FOXO factors have been lim-
ited only to certain aspects [9].
In anticancer drug discovery, much effort is directed
towards identifying small molecule inhibitors of PI3K/Akt
signaling using cell based high content screening. In par-
ticular, monitoring the intracellular localization of FOXO
transcription factors has been used to screen large num-
bers of small molecules [10,11]. Despite being commonly
used as a reporter-gene system in drug discovery, luci-
ferase-based transcriptional assays have not been applied
to massive compound screens for PI3K/Akt inhibitors.
Inhibiting the PI3K/Akt pathway causes FOXO3a to
remain in the cell nucleus and subsequently, it induces
the transcription of downstream genes. To take advantage
of these regulatory features we generated the stable
U2transLUC dual assay cell line that expresses FOXO
responsive luciferase activity and GFP labelled FOXO.
Thus, U2transLUC can be used to simultaneously monitor
the intracellular translocation and the transcriptional
activity of FOXO proteins. We have used this cell line in
an attempt to identify small molecules that interfere with
FOXO signaling.
Results
Generation and testing of luciferase reporter gene 
constructs
FOXO proteins drive the transcription of downstream
genes by binding to the TTGTTTAC FOXO responsive
enhancer element, generally referred to as a daf-16 family
protein-binding element (DBE) [12]. To take advantage of
these regulatory features, we engineered several luciferase
reporter constructs that contained one to six copies of the
DBE consensus cassette in front of a SV40 minimal viral
promoter that was linked to a luciferase reporter gene. The
resulting reporter gene construct were designated as pGL-
1xDBE, pGL-2xDBE, pGL-3xDBE, pGL-4xDBE, pGL-
5xDBE and pGL-6xDBE (Fig. 1A), and the luciferase activ-
ity driven by FOXO from these constructs was evaluated
after they were transiently transfected into U2OS osteosa-
rcoma cells. Since endogenous FOXO3a is only weakly
expressed in these cells, ectopic FOXO3a also had to be
expressed to achieve acceptable basal levels of luciferase
activity (data not shown). In transient co-transfection
assays, all the luciferase reporter constructs that carried
FOXO responsive DBE elements produced a significant
increase in luciferase activity when compared to the
empty pGL3-Promoter vector. Constructs that contained
three or six copies of the DBE element conferred signifi-
cantly stronger FOXO-dependent transcriptional activity
than those with one, two, four or five copies (Fig. 1B). A
reporter plasmid that carried three copies of a mutated
DBE (pGL-3xDBEmut) element did not promote signifi-
cant luciferase activity, confirming the specificity of the
original constructs for FOXO-mediated transcriptional
activity.
In order to evaluate the responsiveness of the reporter
constructs to the inhibition of the PI3K/Akt pathway, we
transiently co-transfected the pGL-3xDBE or pGL-6xDBE
construct with FOXO3a into U2OS cells and then treated
them with the PI3K inhibitor, LY294002 (20 μM). Inhibi-
tion of the PI3K pathway increased FOXO-dependent
transcription from both the pGL-3xDBE and pGL-6xDBE
constructs approximately 3-fold (Figure 1B). By contrast,
activation of the PI3K/Akt signaling pathway following
exposure to insulin decreased this luciferase activity. How-
ever, the differences between the transcriptional activity of
FOXO3a in untreated and insulin treated U2OS cells were
small, indicating that steady-state level of PI3K/Akt activ-
ity was already quite high. In addition, to confirm the spe-
cificity of our system we examined the effect of
constitutive FOXO activation by co-expressing the pGL-
3xDBE or pGL-6xDBE reporter construct with FOXO3a-
A3, a constitutively active form of FOXO3a in which the
three PI3K-dependent phosphorylation sites have been
mutated to alanine. The expression of FOXO3a-A3
induced a strong increase in pGL-3xDBE or pGL-6xDBE
driven luciferase activity. Together, these data indicate
that the firefly luciferase-based read-out of FOXO activity
is very specific, and that it provides a large window to
measure any upregulation in the response (e.g. upon the
inhibition of the PI3K/Akt pathway). Since the respon-
siveness of the triple tandem repeat of DBE (pGL-3xDBE)
to PI3K inhibition was slightly higher than that of pGL-
6xDBE, the p3xDBE-luc construct was used to generate the
stable cell assay line, U2transLUC.Page 2 of 10
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We recently reported the use of a high-throughput cellular
imaging assay to monitor the nucleo-cytoplasmic translo-
cation of a GFP-FOXO3a fusion protein in U2OS cells
(U2foxRELOC) for a chemical genetic study [9]. In order
to generate an assay system that combines the benefits of
large-scale image-based analysis and luciferase-based end
point measurements, we examined the compatibility of
transcriptional and translocational reporters expressed in
a single cell line. We first explored whether the GFP-
tagged FOXO protein is still capable of driving luciferase
expression from FOXO responsive reporters. We com-
pared the reporter activity of the pGL-3xDBE construct or
the mutated version (pGL-3xDBEmut) co-expressed with
FOXO-driven transcriptional activity measured by Luciferase production from different reporter gene constructsigure 1
FOXO-driven transcriptional activity measured by Luciferase production from different reporter gene con-
structs. A. Schematic diagram of the luciferase reporter constructs used in this study. One to six copies of the DBE binding 
cassettes were cloned upstream of the luciferase reporter gene in the pGL3-Promoter vector to create the plasmids pGL-
1xDBE, pGL-2xDBE, pGL-3xDBE, pGL-4xDBE, pGL-5xDBE and pGL-6xDBE. The empty pGL3-Promoter vector and a 
reporter plasmid that carries three copies of a mutated DBE (mDBE) region were used as control plasmids. B. Each construct 
was transiently co-transfected with plasmids encoding FOXO3a and Renilla luciferase into U2OS cells, and the luciferase activ-
ities were determined as described in the "Methods" section. The data were normalized to the Renilla luciferase (phRG-TK 
vector) reporter construct and expressed relative to the normalized activity of the pGL3-Promoter vector. The results are 
given as the mean ± SEM of three independent experiments performed in triplicate. C. Basal and induced FOXO-dependent 
transcriptional activity conferred by three or six copies of the DBE binding cassette (grey and black bars, respectively). The 
plasmids pGL-3xDBE or pGL-6xDBE were transiently co-transfected into U2OS cells with plasmids encoding wild type 
FOXO3a or the constitutively active FOXO3a-A3 and Renilla luciferase. Where indicated cells were treated with 20 μM 
LY294002 or insulin for 6 hours.
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FOXO3a. Hence, we transiently transfected untagged
FOXO3a and EGFP-FOXO3a into U2OS cells and meas-
ured the luciferase activities 4 hours after exposure to
LY294002 or DMSO. The N-terminal EGFP tag did not
significantly affect transcriptional function of FOXO3a in
U2OS cells (Fig. 2) indicating the compatibility of lumi-
nescent and fluorescent read-outs in a single cell line. In
addition, we compared the level of luciferase activity
driven by the pGL-3xDBE construct in the context of sta-
ble EGFP-FOXO3a expression in U2foxRELOC cells [9]
and with the transient co-expression of the fluorescent
fusion protein. The luciferase expression in the presence
of stable EGFP-FOXO3a expression was only slightly
lower than that in U2OS cells transiently overexpressing
EGFP-FOXO3a. To stably integrate the pGL-3xDBE con-
struct into the genome of U2foxRELOC cells, we modified
the pGL3-promoter construct by inserting a puromycin-
resistance cassette to obtain pGLpuro-3xDBE. Puromycin-
resistant stable clones were generated (U2transLUC) and
one was chosen for further use based on FOXO-induced
luciferase activity.
The use of GFP fusion protein for normalization
We examined whether the expression of the GFP fusion
protein could be used to normalize the transcriptional
reporter gene to the changes in cell viability. U2transLUC
cells were seeded and allowed to attach to the wells over-
night. Subsequently, they were incubated with increasing
doses of sodium azide, a known inhibitor of the respira-
tory chain that provokes necrosis in many cell types
[13,14]. Cell viability was estimated through a crystal vio-
FOXO3a and GFP-FOXO trigger a similar induction of luciferase activitiesigure 2
FOXO3a and GFP-FOXO trigger a similar induction of luciferase activities. pGL-3xDBE or pGL-3xDBEmut were 
transiently co-transfected with plasmids encoding FOXO3a or GFP-FOXO3a into U2OS cells. U2foxRELOC cells that stably 
express the GFP-FOXO3a protein (9) were transiently transfected with pGL-3xDBE. LY294002 (20 μM, hatched bars) or 
DMSO (black bars) were added to the transfected cells six hours before processing the cells to assay the luciferase assay. The 
values are the means ± SEM of relative luciferase activities from three independent experiments performed in triplicates.
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ured in each well. Both methods take advantage of the fact
that when epithelial cells undergo apoptosis or necrosis,
they detach from plates and are no longer detectable by
these assays. After a 6 hour exposure to 0.05% sodium
azide the viability of U2transLUC cells was slightly
reduced with no significant differences between crystal
violet or fluorescent intensity read-outs. Higher doses of
sodium azide dramatically compromised U2transLUC
viability, as reflected by both measures of viability. A nor-
malization procedure using crystal violet staining or the
GFP-FOXO mediated fluorescent signal resulted in similar
indices of viability (Fig. 3), indicating that the fluorescent
reporter protein can be used to monitor the viability of
U2transLUC cells.
Multiplexed U2transLUC assay
The U2transLUC-based assay was formatted for 96-well
plates and the workflow has been automated. To assess
the specificity of the transcriptional and the transloca-
tional read-out, we challenged the U2transLUC system
with small molecule inhibitors under living cell condi-
tions in order to observe the translocation of the fluores-
cent reporter protein and luciferase activity as the
transcriptional end point. We exposed U2transLUC cells
to a panel of test compounds with known biological activ-
ity. Three different doses were used that resulted in a range
of final concentrations greater than two orders of magni-
tude around the IC50 value for each individual compound.
The live cells were stained with the fluorescent nuclear dye
DRAQ5 and images were obtained on an automatic
microscope. The nuclear/cytoplasmic (Nuc/Cyt) fluores-
cence intensity ratios were determined and the percentage
of cells per well displaying nuclear translocation or the
inhibition of nuclear export was calculated. Compounds
that induced the nuclear accumulation of the fluorescent
signal above 60% of that obtained from wells treated with
LY294002 were considered as hits. Several compounds
known to inhibit PI3K activity or the nuclear export
machinery fulfilled these criteria (Fig 4A). As expected
from the results of a previous study in U2foxRELOC cells
[9,15], the PI3K inhibitors PI-103 and LY294002 were
Viability of U2transLUC cells using crystal violet assay or by monitoring the GFP-intensity per wellF gure 3
Viability of U2transLUC cells using crystal violet assay or by monitoring the GFP-intensity per well. U2transLUC 
cells were exposed to 0.05%, 0.10%, 0.25%, 0.50% or 1% sodium azide for three hours and processed as described in the 
"Methods" section. The values are the means (± SD) of GFP intensity per well or the absorbance at 595 nm from three inde-
pendent experiments.
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of U2transLUC cells. By contrast, known activators of the
PI3K/Akt pathway produced little nuclear localization of
GFP-FOXO, including EGF, IGF and PDGF. The exposure
of U2transLUC cells to the nuclear export inhibitors lep-
tomycin B or ratjadone A provoked the nuclear accumula-
tion of fluorescent signal, as shown previously for
U2foxRELOC cells [9,15]. Conversely, through the meas-
urement of the FOXO-dependent production of firefly
luciferase, leptomycin B and ratjadone A exerted no signif-
icant effect on the transcriptional activity of FOXO (Fig
4B). Finally, exposure to PI-103 and LY294002 triggered a
dramatic increase in FOXO-dependent luciferase activity.
Together, these data show that the U2transLUC assay
serves as an automated high throughput assay that can
identify inhibitors of PI3K/Akt signaling through the high
content analysis of protein translocation in conjunction
with an independent analysis of the transcriptional activ-
ity of FOXO transcriptions factors.
Discussion and conclusion
FOXO transcription factors are tightly regulated at differ-
ent levels, including their intracellular translocation and
transcriptional activity [1,3]. Here we report the genera-
tion of a multiplexed assay system that is capable of
simultaneously monitoring these signaling events. The
assay system is based on U2transLUC cells that stably
express two different reporter constructs. The intracellular
translocation of FOXO factors is followed using a fluores-
cent tagged FOXO reporter protein, whereas transcrip-
tional activity is monitored via FOXO-dependent
luciferase production. We show here that the fluorescent
and luminescent read-outs are compatible in the same
cell.
The design of the U2transLUC screen presented here
offers some major advantages over more classical cellular
assays. Primary and secondary screens of small molecule
compounds are usually performed in different cell sys-
tems. By contrast, the U2transLUC provides the possibil-
ity of using two different read-outs within the same
experiment, enabling a direct comparison of the hits from
each of these. These hits might be divided into transloca-
tion, transactivation and dual hits, and they may in turn
be analyzed according to a corresponding hit ranking. The
U2transLUC assay does not need the introduction of addi-
tional plasmids and hence, it avoids the limitations asso-
ciated with transfection procedures.
The use of the GFP-FOXO fusion protein provides a mul-
tifunctional tool that allows for versatile assay read outs,
measurement of cell viability/number and sorting and
maintaining a homogeneous cell assay population. We
show that the fluorescent signal from the GFP-FOXO
fusion protein is suitable to monitor viability and it can be
used to normalize the values obtained by measuring fire-
fly luciferase activity. Furthermore, the fluorescent FOXO
functions as a reporter protein for FOXO translocation
and as an effector protein that drives DBE-dependent
luiferase production. On the other hand the GFP-FOXO
fusion protein offers the possibility to control the level of
expression of the transcriptional effector in the luciferase
assay, and at the same time it serves as a sorting tool to
maintain a homogenous cell population. Thus, the multi-
functional use of GFP-FOXO allows also to reduce the var-
iability of the assay. The U2transLUC is an image based
high throughput assay that enables compounds that pro-
duce artifacts and cytotoxicity to be identified on a single
cell basis. Finally, the U2transLUC assay design might be
adaptable to any transcription factor that undergoes
nucleo-cytoplasmic shuttling. We challenged the
U2transLUC system with chemical agents with known
biological activity and were able to identify known PI3K
inhibitors as double-hits that score in the translocation
and the transactivation read-out. By contrast, chemical
probes that inhibit the general nuclear export machinery
Validation of U2transLUC assay using a panel of test compoundsFigure 4 (see previous page)
Validation of U2transLUC assay using a panel of test compounds. A. The nuclear accumulation of the GFP-FOXO 
reporter protein and FOXO driven luciferase activity induced by the test compounds. We exposed U2transLUC cells to three 
different concentrations of the test compounds. The results shown here are the values obtained from the treatment of 
U2transLUC cells with 4 nM Ratjadone A, 20 μM LY294002, 1 ng/ml PDGF, 100 μM Minerval, 1 μM Forskolin, 4 nM Leptomy-
cin B, 30 μM Cisplatin, 100 nM PI-103, 0.5 nM Rapamycin, 20 ng/ml IGF, 5 ng/ml EGF and Dimethyl sulfoxide (DMSO) as a neg-
ative control. The grey bar graphs and the corresponding left hand y-axis depict the values in relation to the control values 
normalized to the corresponding measure of viability values. The relative luciferase activity was calculated dividing the value 
obtained for Firefly luciferase activity for each well by the average GFP intensity from the same well. The right hand y-axis and 
the hatched bars indicate the percentage of cells in each well exhibiting nuclear/cytoplasmic (Nuc/Cyt) ratios of fluorescence 
intensity greater than 1.8 normalized to the percentage in DMSO-treated wells. B. Representative images of treated cells using 
high throughput format of the U2transLUC system. Images of cells expressing GFP-FOXO and stained with DRAQ5 were 
obtained by automated microscopy 2 hour after drug exposure. The images correspond to U2transLUC cells exposed to 4 nM 
Ratjadone A, 4 nM Leptomycin B, 20 μM LY294002, 100 nM PI-103 and DMSO. The images are shown from the GFP and 
DRAQ5 channels, as well as the corresponding merged image in the case of the DMSO treated control cells.Page 7 of 10
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although GFP-FOXO was trapped in the cell nucleus.
In summary, our data demonstrate that U2transLUC is a
sensitive and robust assay to identify small-molecule
inhibitors of signaling events that regulate the subcellular
localization and/or the transcriptional activity of FOXO
proteins. The signaling events identified here include
PI3K/Akt signaling and nuclear export. Our data raise the
expectation that a more extensive chemical interrogation
of the U2transLUC read-outs could lead to the identifica-
tion of new molecular targets and small molecules that
might contribute to the development of more potent ther-
apeutic agents to treat tumors.
Methods
Compound supply and recombinant proteins
All chemicals were purchased from commercial sources
except for the PI3K inhibitor PI-103, which was synthe-
sized following published patent specifications. Cisplatin
was provided by C. Navarro, Minerval was generously
provided by P. Escriba, and all other chemicals were pur-
chased from commercial sources: LY294002, Ratjadone A,
were purchased from Calbiochem (San Diego, CA); For-
skolin, Leptomycin B and Rapamycin, were purchased
from LC Laboratories (Woburn, MA, U.S.A.); DMSO was
purchased from Sigma-Aldrich (St. Louis, USA); Epider-
mal growth factor (EGF), platelet-derived growth factor
(PDGF) were purchased from RELIATech A.S. (Braunsch-
weig, Germany); and human Insulin-Like Growth Factor-
I (IGF-I) and human insulin were purchased from (Roche
Diagnostics, Mannheim, Germany). Stock solutions of
the test compounds were deposited in three different con-
centrations in 96-well master plates, transferred to multi-
ple replica plates and frozen at -80°C.
Plasmids
The luciferase reporter constructs pGL-1xDBE, pGL-
2xDBE, pGL-3xDBE, pGL-4xDBE, pGL-5xDBE and pGL-
6xDBE were generated by inserting one to six copies of the
DBE consensus sequence [12] in front of a SV40 minimal
viral promoter of the pGL3-Promoter vector (Promega).
The annealed and phosphorylated oligonucleotides 5'-
CTAGAAGTAAACAA-3' (1xDBE-forward) and 5'-
GATCTT-GTTTAC-3' (1xDBE-reverse) or 5'-CTAGAAG-
TAAACAACTATGTAAACAA-3' (2xDBE-forward) and 5'-
GATCTTGTTTACATAGTTGTTTACTT-3' (2xDBE-reverse)
were ligated as single copy or concatemerized into NheI
and BglII digested pGL3 promoter vector. In order to gen-
erate the negative control plasmid pGL-3xDBEmut, three
copies of a DBE sequence that contains a point mutation
that prevents FOXO binding (annealed and phosphor-
ylated oligonucleotides (3xmDBE-forward) 5'-CTA-
GAAGTA-AGCAACTATGTAAG-CAACTATGTAAGCAA-3'
and (3xmDBE-reverse) 5'-GAT-CTTGCTTACATAGTTGCT-
TACATAGTTGCT-TACATAG-3') were inserted into pGL3-
Promoter vector. The constitutively active construct
FOXO3a-A3, in which three PI3K-dependent phosphor-
ylation sites have been mutated to alanine was kindly pro-
vided by Dr. M. Hu (University of Texas M. D. Anderson
Cancer Center, Houston). In order to generate stable cell
lines for the assay, we inserted a puromycin-resistance cas-
sette into the pGL-3xDBE construct. This was achieved by
PCR amplifying the puromycin resistance gene from pBA-
BEpuro vector and cloning it into the SalI and BamHI sites
of the pGL3-Promoter vector derived pGL-3xDBE con-
struct, thereby obtaining pGLpuro-3xDBE.
Cell culture
U2-OS cells obtained from the ATCC were cultivated in
Dulbecco's modified Eagle's medium (DMEM), supple-
mented with 10% fetal bovine serum (FBS, Sigma), anti-
biotics and antimycotics in a humidified incubator at
37°C with 5% CO2. U2foxRELOC cells have been
described previously [9].
Transfection and Luciferase assays
U2OS cells were cultured in a 96-well plate (100 μl final
volume per well) and transfected at 70% confluence with
the plasmids indicated using the effectene transfection
reagent (Qiagen). LY294002 or insulin were added indi-
vidually to wells 42 hours later, at a final concentration of
20 μM or 5 mg/ml, respectively, and the cells were incu-
bated for an additional 6 h. Luciferase assays were carried
out using the Dual-Luciferase Reporter Assay System
(Promega), according the manufacturer's instructions on
a multilabel plate reader (Wallac Victor, Perkin-Elmer),
and the ratio of firefly- to Renilla-luciferase activities was
calculated. All values were presented as means ± SEM. The
unpaired t-test (two-tailed) was performed for statistical
analysis using the GraphPad PRISM® Version 4.0 program.
Differences with a p value < 0.05 were considered statisti-
cally significant.
Generation and maintenance of U2transLUC cells
U2foxRELOC cells were transfected at 75% confluence
with pGLpuro-3xDBE using the effectene transfection rea-
gent (Qiagen). Cells were selected with puromycin (Calbi-
ochem) for five days and the resistant colonies that best
expressed the reporter constructs were then recovered and
cultured, as was the most homogeneous population. Flu-
orescence-activated cell sorting (FACS) of GFP-FOXO
expressing cells was performed on a FACSAria (BD Bio-
sciences, San Jose, CA, USA). U2transLUC cell clones were
maintained in DMEM, supplemented with 10% FBS
(Sigma), antibiotics and antimycotics, 0.1 mg/ml Neomy-
cin and 1 μg/ml puromycin. Cell cultures were main-
tained in a humidified incubator at 37°C with 5% CO2,
and they were passaged when confluent using trypsin/
EDTA.Page 8 of 10
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Triplicate samples of 104 cells were seeded in 2.5 cm
dishes and allowed to attach. After 24 hours, the medium
was removed and replaced with culture medium with
sodium azide at the concentrations indicated, while the
controls remained untreated. After the appropriate time
period the cells were fixed with 0.5% glutaraldehyde and
stained with 1% crystal violet. After extensive washing,
crystal violet was resolubilized in 10% acetic acid and
quantified at 595 nm as a relative measure of cell number.
Viability assay measuring fluorescent intensity
Samples of 104 cells per well were allowed to attach over-
night in 96-well Greiner plates and the following day the
culture medium was replaced with fresh medium contain-
ing the concentrations of sodium azide indicated. After a
three hour treatment, the cells were washed with PBS and
the fluorescent intensity was measured in a multilabel
plate reader (Wallac Victor 2, Perkin-Elmer) using UV
light as the excitation source, as well as a F485 CW lamp
Filter and a F535 CW emission filter for 0.5 seconds per
well. The values are the averages obtained from experi-
ments carried out in triplicate.
U2transLUC assay
U2transLUC cells were seeded at a density of 1.0 × 105
cells/ml in black-wall clear-bottom 96-well microplates
(BD Biosciences) using a Titan Multidrop 384 automatic
dispenser (Titertek Instruments, Inc., Huntsville, AL). The
final volume of the cell suspension was 200 μl in each
well. After incubation at 37°C in 5% CO2 for 12 hours, 2μl of each test compound was transferred from the master
plate to the assay plate. Cells were incubated in the pres-
ence of the compounds for 1 hour and the far-red fluores-
cent cell-permeable DNA probe, DRAQ5™ (Biostatus Ltd,
Leicestershire, UK), was then added to all wells at a final
concentration of 5 mM 15 minutes prior to obtaining the
images. The images were acquired as described previously
[16] using a BD Pathway™ 855 Bioimager equipped with
a incubation chamber that provided a constant tempera-
ture of 37°C in 5% CO2. Images were acquired in the GFP
and DRAQ5 channels using 488/10 nm EGFP excitation
filter, a 515LP nm EGFP emission filter and 635/20 nm/
695/55 nm DRAQ5 excitation/emission filter with a 10×
dry objective. The plates were exposed for 0.066 ms (Gain
31) to acquire DAPI images and 0.55 ms (Gain 30) for
GFP images. Image and data analysis was performed as
described previously [15]. After image acquisition, the
plates were incubated for another 5 hours at 37°C and
then the average GFP intensity per well was measured as
described above. Finally, U2transLUC cells were proc-
essed to measure the firefly luciferase activity using the
Luciferase Assay System (Promega) on a multilabel plate
reader (Wallac Victor, Perkin-Elmer) according to the
manufacturer's instructions. The relative luciferase activ-
ity, as a measurement of FOXO3a's transcriptional activity
was calculated dividing the value obtained for Firefly luci-
ferase activity for each well by the the average GFP inten-
sity from the same well.
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